2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1573

Plasma Pentraxin 3 Concentration Is Associated with Progression of Radiographic Joint Damage but Not with Carotid Atherosclerosis in Female Patients with Rheumatoid Arthritis: Results from a 3-Year Prospective Study
Abstract Number: 1574

Associations of Serum Anti-Malondialdehyde-Acetaldehyde (MAA) Antibodies with Cardiovascular and Respiratory Mortality in Men with Rheumatoid Arthritis
Abstract Number: 1575

Serum Vascular Cell Adhesion Molecule-1 (VCAM-1) Levels Are Associated with Vascular Dysfunction and Increased Cardiovascular Risk in an Animal Model and Patients with Rheumatoid Arthritis
Abstract Number: 1576

Effect of Conventional Synthetic and Biological Disease Modifying Anti-Rheumatic Drugs on the Immunogenicity of Hepatitis B Vaccine in Patients with Rheumatoid Arthritis
Abstract Number: 1577

Periodontal Evaluation Is Associated with Increased Likelihood of Achieving Low Disease Activity in Rheumatoid Arthritis with Methotrexate
Abstract Number: 1578

Serum Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Are Associated with Subclinical Interstitial Lung Disease in the Multi-Ethnic Study of Atherosclerosis: A Population-Based Study
Abstract Number: 1579

Association of Myocardial Abnormalities with N-Terminal Pro-Brain Natriuretic Peptide and Disease Activity in Rheumatoid Arthritis without Cardiac Symptoms, Assessed By Cardiac Magnetic Resonance Imaging
Abstract Number: 1580

Abnormal High Density Lipoproteins in Synovial Fluid from Patients with Rheumatoid Arthritis Compared to Patients with Non-Inflammatory Arthritis
Abstract Number: 1581

Cardiac Involvement in Patients with Amyloid a Amyloidosis Due to Rheumatoid Arthritis
Abstract Number: 1582

Joint Damage Associated with Loss of Body Mass in Rheumatoid Arthritis
Abstract Number: 1583

Identifying Risk Factors for Progression of Rheumatoid Arthritis-Associated Interstitial Lung Disease
Abstract Number: 1584

Metabolic Syndrome Is Associated with Disease Activity in Patients with Rheumatoid Arthritis: A Prospective Cohort Study
Abstract Number: 1585

Vaccination Uptake in Patients with Rheumatoid Arthritis Treated with Disease-Modifying Anti-Rheumatic Drug Therapy: A Retrospective Cohort Study Using UK Primary Care Electronic Medical Records
Abstract Number: 1586

Weight Loss in Obese Rheumatoid Arthritis (RA) Patients Improves Disease Activity without Modifying RA Treatment
Abstract Number: 1587

Deriving a Comorbidity Index Form the Meddra Classification: Performance of Rheumatic Disease Comorbidity Index, Charlson-Deyo Index and Functional Comorbidity Index Among Patients with RA in NOR-DMARD Cohort

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].